3 key trends shaping the immunology market

From an increase in sales of interleukin inhibitors to the prevalence of biosimilars, this decade has been an eventful one in the immunology industry.

Ligelizumab could top Xolair in chronic hives, says Novartis

Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthrit...

J&J filing aims Tremfya at crowded psoriatic arthritis marke...

FDA agrees to downsized trial for Calliditas' rare disease d...

The FDA has just made it easier for Sweden’s Calliditas to develop Nefecon for a rare kidney disease, accepting a faster readout that should hasten development of the drug.

Amgen stumps up $13.4bn to claim Otezla from Celgene